Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Arianna Vignini, Alessia Giulietti, Laura Nanetti, Francesca Raffaelli, Lucia Giusti, Laura Mazzanti and Leandro Provinciali
Affiliation: Department of Clinical Science, Section of Biochemistry, School of Medicine. Universita Politecnica delle Marche, Via Tronto 10 A, 60020 Ancona, Italy.
Keywords: Type 2 Diabetes, Alzheimer's disease, Statins, Liraglutide, Metformin
Several research groups have begun to associate the Alzheimer Disease (AD) to Diabetes Mellitus (DM), obesity
and cardiovascular disease. This relationship is so close that some authors have defined Alzheimer Disease as Type 3
Diabetes. Numerous studies have shown that people with type 2 diabetes have twice the incidence of sporadic AD.
Insulin deficiency or insulin resistance facilitates cerebral β-amyloidogenesis in murine model of AD, accompanied by a
significant elevation in APP (Amyloid Precursor Protein) and BACE1 (β-site APP Cleaving Enzime 1). Similarly, deposits
of Aβ produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway.
Furthermore, as it is well known, these disorders are both associated to an increased cardiovascular risk and an altered
cholesterol metabolism, so we have analyzed several therapies which recently have been suggested as a remedy to treat
together AD and DM.
The aim of the present review is to better understand the strengths and drawbacks of these therapies.
Rights & PermissionsPrintExport